In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as a performance measure for quantifying the quality of care.

Kansas City Cardiomyopathy Questionnaire (KCCQ-12) The following questions refer to your heart failure and how it may affect your life. Please read and complete the following questions. There are no right or wrong answers. Please mark the answer that best applies to you. 1. Heart failure affects different people in different ways. Some feel ...

2020年4月9日 · This qualification statement supports the KCCQ-23 Total Symptom Score, Physical Limitations Score and Clinical Summary Score as measures of their respective concepts in drug development.

2020年11月17日 · In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as a performance measure for quantifying the quality of care.

2020年11月17日 · This review describes how to interpret the KCCQ, how it should be analyzed in clinical trials to maximize the interpretability of results, and how it can be used in clinical practice and population health.

The Clinical Summary Score (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome instrument, provides a measure of symptoms and physical limitations associated with heart failure.

In April 2020, the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) approved the use of the Kansas City Cardiomyopathy Questionnaire (KCCQ) as a primary endpoint in drug trials for patients with heart failure (HF). 1 Noted in the FDA approval is a recommendation to establish thresholds for clinically ...

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a new, self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life.

2020年11月1日 · In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as a...

Background—Improving functional status and quality of life are important goals of treatment for patients with severe aortic stenosis. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure health status measure and has been used in studies of patients with aortic stenosis.